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Abbrevations 
 ADT Androgen deprivation therapy 
AJCC   American joint committee on cancer 
ASTRO The American Society for Therapeutic Radiology 
and Oncology 
bNED No evidence of disease activity measured 
biochemically, i.e. PSA normal or not detectable 
C-ion Carbon ion 
CRT Conformal radiotherapy 
CSS Cancer specific survival 
CT Computer tomography 
CTC Common toxicity criteria 
CTV Clinical target volume 
DRE Digital rectal examination 
DVH Dose volume histogram 
EBRT External beam radiation therapy 
FDA Food and drug administration 
GI Gastrointestinal 
GTV Gross tumor volume 
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GU Genitourinary 
HDR High dose rate brachytherapy 
HRPC Hormone refractory prostate cancer 
HT Hormone therapy 
ICRU International commission on radiation units and 
measurements 
IMRT Intensity- modulated radiotherapy 
ITV Internal target volume 
LDR  Low dose rate brachytherapy 
LHRH Luteinising hormone releasing hormone 
MAB Maximal androgen blockade 
MLC Multileaf collimator 
MRI Magnetic resonance imaging 
NCCN National comprehensive cancer network 
NUCG Norwegian Urological Cancer Group 
OR Organ at risk 
OS Overall survival 
PC Prostate cancer 
PET Positron-emission tomography 
PSA Prostate specific antigen 
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PTV  Planning target volume 
QoL Quality of life 
RP Radical prostatectomy 
RT Radiation therapy 
RTOG Radiation Therapy Oncology Group 
SIB Simultaneous integrated boost 
SPECT Single-photon emission CT 
TNM Tumour node metastasis system, UICC 
classification 
TURP Transurethral resection of prostate 
UICC International union against cancer 
WHO World Health Organisation 
WW Watchful waiting 
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1. General introduction 
1.1 Epidemiology 
Prostate cancer (PC) is the most common cancer in men in Europe, North America, 
and some parts of Africa [1], and is a large and growing public health problem.  
Incidence of PC is steadily increasing in almost all countries, yet we know little about 
what causes this disease.  In Norway, with a total population of 4.7 million people, 
3817 new cases of PC were diagnosed in 2006 (95.3 per 100,000), making it the most 
common cancer in Norway [2]. The mortality in 2004 was 1074 (20.5 per 100,000). 
The natural ageing of the population, combined with the continued and widespread 
use of improved diagnostic tests such as serum prostate specific antigen (PSA), 
contributes to the increase in the numbers of men diagnosed with localised PC.                                   
  
Figure 1: Age-specific incidence of prostate cancer in Norway 2000-2004 [3] 
PC is rare before age 50 years, thereafter the incidence increases steeply with age 
(Figure 1). 
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Figure 2. Time trend in incidence and mortality of prostate cancer in Norway, in relation to use of PSA testing 
[4]. 
PC is a disease of the elderly; around the world, three-quarters of cases occur in men 
aged ≥  65 years [5]. The incidence of PC has been increasing the last 20 years, but 
mortality is now decreasing also in Norway (Figure 2). PC mortality rate in Norway 
are among the highest in the world [5]. From 1996 to 2004 mean annual decline in 
PC mortality rates in Norway was 1.8% [4]. 
The rapid increase in incidence during the early 1990s coincided with the 
introduction of the PSA test and conveys little information about the occurrence of 
potentially lethal disease. Mortality rates, however, have recently stabilized or 
declined in countries where PSA testing and curative treatment have been commonly 
practiced since the late 1980s [4]. PSA became available in the Nordic countries 
around 1990 [6]; rapid increases in PSA testing were associated with sharp increases 
in PC incidence (Figure 2).  
Several reviews of the evidence on the causes and risk factors for PC have been 
published but the causes remain essentially unknown [1, 7]. The strongest risk factor 
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for PC is age, but hereditary factors (genes), race, dietary factors, and lifestyle-related 
factors contribute to the development of PC [8]. Finasteride, a selective inhibitor of 
5α-reductase, inhibits the conversion of testosterone to dihydrotestosteron, taken for 7 
years in the Prostate Cancer Prevention Trial reduced the prevalence of PC by 24.8 % 
versus placebo in 18882 men randomized to treatment with that agent [9]. Despite 
this definitive evidence of risk reduction, finasteride has generally not been accepted 
clinically because the first analyses showed increased risk of high-grade PC in the 
finasteride group. The results from radical prostatectomy (RP) have recently been 
reported and suggest that grading artefacts in biopsy Gleason scoring may have 
occurred [10-12]. 
With the more widespread use of screening, the prevalence of latent PC has decreased 
3-fold (USA) [13]. In the period 1955-1960 vs. 1991-2001, the prevalence of latent 
PC detected only at autopsy in men older than 40 years was 4.8% compared to 1.2%, 
respectively. It appears that there is a shift toward lower stage and grade among the 
latent PC diagnosed at autopsy in the more recent period. However, a similar 
decrease in the prevalence of autopsy detected cancer was observed in Norway 
between 1957 and 1991, when there was no coordinated screening [14]. The 
proportion of PC reported to the Norwegian Cancer Registry as having been detected 
at autopsy between 1957 and 1961, 1977 and 1981, and 1987 and 1991 was 2.3%, 
2.8% and 1.6%, respectively. A potential explanation for this finding is sampling 
error since the autopsy rate in Norway decreased significantly during this period. The 
median age at diagnosis in Norway in the period 1987-1991 was 75.1 years. 
About one third of all patients in Norway under the age of 75 years with recently 
diagnosed PC were treated with curative intention in 1998 and 2001 (1998:28%, 
2001:33%), but in Western- Norway it was 39% and 41% [15]. Data from the 
Norwegian Cancer Registry show that five years relative survival in Norway 1995-
1999 was 74.9% and in Western-Norway 79.9%, probably reflecting a more active 
attitude for curative treatment, offering both surgery and radiation as treatment. 
Curative radiotherapy has increased in Haukeland University Hospital in the study 
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period (Figure 3), and in addition Stavanger University Hospital has offered curative 
radiation therapy since 1999. 
0
20
40
60
80
100
120
140
160
1988 1990 1992 1994 1996 1998 2000 2002
year
nu
m
be
r
 
Figure 3. Number of prostate cancer patients having curative radiation treatment at Haukeland University 
Hospital in the period 1990 – 2001.  
1.2 TNM categorisation of prostate cancer 
The Tumour Node Metastases (TNM) classification system is the internationally 
accepted system for staging malignant tumour. The first uniform staging system for 
PC was published by the American Joint Committee on Cancer (AJCC) and the 
International Union Against Cancer (UICC) in 1992, after earlier versions dating 
back to 1978 [16, 17]. The TNM staging system is used for treatment planning, 
prognosis estimation and evaluation of treatment results. 
Two classifications are described for PC, clinical classified TNM (or cTNM) is based 
on evidence acquired before treatment. Such data arises from physical examination 
(digital rectal examination (DRE)), ultrasound, chest radiography, bone scan, PSA 
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and biopsy. For pathological classification, pTNM, histologic examination of the 
resected specimen is required after RP and lymph node sampling. The TNM system is 
used to numerically describe the anatomical extent of cancer and is based on three 
components: T, extent of the primary tumour; N, absence or presence of the disease 
in the regional lymph nodes; M, absence or presence of distant metastases [18]. The 
addition of number to these components indicates the extent of malignant disease. 
The M category is examined by chest X-ray and bone scan.  
The TNM system thus incorporates a clinical and a pathological evaluation and has 
been revised in 2002 [19]. The present study applies the 1992 [20] and 1997 version 
[21]. The clinical stage is essential to select and evaluate therapy, while the 
pathological stage provides the most precise data to estimate prognosis and calculate 
end results [19].       
In practice we have included patients in the following categories: stage T1c (often 
denoted T1), T2, T3 and T4. 
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  Table 1. UICC-TNM staging system (1992)  
T Primary tumour 
Tx Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
T1 Clinically unapparent tumour not palpable or visible by imaging 
 T1a Tumour, an incidental histological finding in 5% or less of tissue resected 
 T1b         Tumour, an incidental histological finding in more than 5% of tissue resected 
 T1c Tumour identified by needle biopsy  
T2 Tumour confined within prostate 
 T2a Tumour involves half a lobe or less 
 T2b Tumour involves more than half a lobe but not both lobes 
                T2c         Tumor involves both lobes  
T3 Tumour extends through prostate capsule 
 T3a         Unilateral extracapsular extension 
                T3b        Bilateral extracapsular extension  
 T3c         Tumour invades seminal vesicle(s) 
T4 Tumour is fixed or invades adjacent structures other than seminal vesicles 
                T4a         Fixed or invades adjacent structures; bladder neck, external sphincter, rectum 
                T4b         Tumor invades levator muscles, fixed to pelvic wall 
 N Regional lymph node(s) 
Nx Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in a single regional lymph node < 2 cm 
N2 Metastasis in a single regional lymph node > 2 cm but not > 5 cm 
N3 Metastasis in regional lymph node > 5 cm in greatest dimension 
M Distant metastasis 
Mx Presence of distant metastasis cannot be assessed 
M0 No distant metastasis 
M1a Non-regional lymph node(s) 
M1b Bone(s) 
M1c Other sites 
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  Table 2. UICC-TNM staging system (1997)  
T Primary tumour 
Tx Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
T1 Clinically apparent tumour not palpable or visible by imaging 
 T1a Tumour incidental finding in 5% or less of tissue resected 
 T1b Tumour incidental finding in more than 5% of tissue resected 
 T1c Tumour identified by needle biopsy (e.g. because of elevated PSA) 
T2 Tumour confined within prostate 
 T2a Tumour involves one lobe 
 T2b Tumour involves both lobes  
T3 Tumour extends through prostate capsule 
 T3a Extracapsular extension (unilateral or bilateral) 
 T3b Tumour invades seminal vesicle 
T4 Tumour is fixed or invades adjacent structures other than seminal vesicles: bladder neck, external sphincter, 
rectum, levator muscles and/or pelvic wall 
N Regional lymph nodes 
Nx Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Regional lymph node metastasis 
M Distant metastasis 
Mx Presence of distant metastasis cannot be assessed 
M0 No distant metastasis 
M1a Non-regional lymph node(s) 
M1b Bone(s) 
M1c Other site(s) 
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1.3 Histology 
In Norway up to 2001, grading of PC was commonly performed according to the 
World Health Organisation (WHO) system. The WHO grading system takes into 
account the degree of nuclear anaplasia (nuclear grades) and the pattern of glandular 
differentiation (histologic grades) [22]. 
A widely acknowledged method of grading the aggressiveness of PC was developed 
by Donald F Gleason between 1969 and 1974, based solely on the architectural 
pattern of the tumour (Figure 4). Now the Gleason score is the most frequently used 
grading system for PC [23, 24]. 
 
 
Figure 4. Schematic diagram of Gleason grading system [24] 
Grade 1 (well differentiated), circumscribed mass of evenly spaced, closely packed, 
uniform shaped glands, with no evidence of infiltration of the stroma. 
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Grade 2 (well differentiated), some infiltration into the surrounding stroma and more 
variation in gland size and spacing, although this is limited. 
Grad 3 (moderately differentiated), most common grade with more variation in size, 
shape, and separation of the glands, less defined boundaries, and less intervening 
stroma. 
Grad 4 (poorly differentiated), fusion of the glands forming a solid anastamosing 
network with a ragged invasive edge. 
Grad 5 (undifferentiated), characterised by a complete absence of gland formation 
with sheets or clusters of cells. 
Because of the histological variation within each tumour, two grades, the 
predominant or primary grade, and the less extensive, or secondary grade, were 
recorded in each case, and then summed. For consistency, if only one grade was 
present, this was doubled. Then the outcome was reported as the Gleason score (score 
2 – 10) [24]. Weaknesses in the Gleason grading system is that growth patterns that 
do not constitute the primary or secondary patterns (i.e., the tertiary growth patterns) 
are not reflected in the total score [23]. To deal with this issue, the International 
Society of Urological Pathology held in 2005 a consensus conference to address 
controversial issues surrounding the Gleason grading system [25]. Their 
recommendation regarding tertiary Gleason grade depended on the source of the 
specimen. For needle biopsy specimens, both the primary patterns and the highest 
grade should be recorded. For RP one assigns the Gleason score based on the primary 
and secondary patterns with a comment as to the tertiary pattern.  
The Gleason score is routinely categorised into a three-tiered Gleason scoring system, 
scores 2-6, score 7 and score 8-10 [26]. Gleason score 7 tumours have been shown to 
behave significantly worse than Gleason score 5-6 tumours [27], but have a better 
prognosis than Gleason score 8-9 tumours [28]. Gleason score 7 tumours are 
heterogeneous in their biologic behaviour. The major prognostic shift is between 6 
and 7, with further sub classification of score 7 to 3+4 or 4+3 with worse prognosis 
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associated with 4+3 [26]. The differences in prognosis for patients with Gleason 
scores 3+4 and 4+3 tumours at radical prostatectomy are significant [29-33]. A study 
by Patel and co workers [34], showed that men with PC having biopsy Gleason score 
7 and tertiary grade 5 had a higher risk of PSA-failure when compared with men with 
Gleason score 7 without tertiary grade 5 and had a comparable risk with men with 
Gleason score 8 to 10.  
The Gleason grading on prostate biopsy is a poor predictor of pathological outcome 
after RP, both undergrading and overgrading are considerable as only 29.2 % had 
identical grading in a reported study [35]. When grouped into more meaningful 
categories, Gleason 2-4, 5-6, 7 and 8-10, the correlation improved, with 48.5 % of 
patients remaining in the same group after RP [35]. There are also inter-observer 
variation in the reporting of Gleason scores for diagnostic biopsies, low grade 
tumours are often upgraded when reviewed by experts in urological pathology [36, 
37]. 
It is now considered unacceptable to score Gleason sum 2-4 on diagnostic biopsies 
[36], because low-grade cancer are mostly located anteriorly in the prostate within the 
transition zone and tend to be small [38].                                                                    
1.4 PSA 
PSA is a single-chain glycoprotein produced almost exclusively by the epithelial 
component of the prostate gland [39], with a molecular weight of 33 kD and is about 
7% carbohydrate. This antigen was initially identified and purified by Wang and 
associates [40] in 1979 from prostatic tissue, and detected in sera obtained from PC 
patients in 1980 [41]. Since the late 1980s PSA has been used widely in the clinical 
setting and has emerged as the most important tumour marker for PC [6, 42].      
PSA is organ specific for the prostate gland, but not cancer specific. The specificity 
of the PSA test is suboptimal; a critical challenge is discriminating benign prostatic                               
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 hyperplasia from PC [39]. Many approaches have been proposed to make this task 
easier, age specific PSA, PSA-density, PSA-velocity and free/total PSA radio [43, 
44]. The serum PSA levels can be temporarily altered by various pharmacological 
therapies, prostatic diseases and urological manipulations [45]. 
In clinical practise measurement of serum PSA supports the diagnosis of PC, 
monitors the efficacy of treatment and may serve as a prognostic tool. 
After RP the majority of men have a rapid decline in serum PSA to undetectable 
levels. As a corollary the failure of PSA to become undetectable is highly suggestive 
of persistent disease after surgery [45]. PSA has been used as a surrogate end point to 
monitor disease activity following prostatic irradiation and this has been a major 
advance in recent years [46-48]. However, response of PSA to irradiation is more 
unpredictable; after radiation therapy PSA level decline more slowly and may not 
reach undetectable levels due to persistence of normal prostate tissue [45].  
There are various guidelines for the interpretation of post radiation PSA profile and 
determination of biochemical failure (i.e. rising PSA). The most widely used 
guidelines are the American Society for Therapeutic Radiology and Oncology 
(ASTRO) [49] guidelines: 
1. Biochemical failure is not justification per se to initiate additional treatment. It 
is not equivalent to clinical failure. It is, however, an appropriate early end 
point for clinical trials. 
2. Three consecutive increases in PSA is a reasonable definition of biochemical 
failure after radiation therapy (RT). For clinical trials, the date of failure 
should be the midpoint between the post irradiation nadir PSA and the first of 
the three consecutive rises. 
3. No definition of PSA failure had, as yet, been shown to be a surrogate for 
clinical progression or survival. 
 
 21
4.     Nadir PSA is a strong prognostic factor, but no absolute level is a valid cut 
point for separating successful and unsuccessful treatments. Nadir PSA is 
similar in prognostic value to pre-treatment prognostic variable. 
The ASTRO definition has been criticized because of its dependence on backdating 
and the erroneous conclusion that may be drawn if the follow-up is inadequate [50-
52]. Also it lacks specificity when androgen deprivation therapy is used, leading to 
biochemical failure misclassification because the PSA level can rise transiently after 
the release of androgen deprivation [53].There is also a potential for false positives 
secondary to “benign PSA bounces” [54, 55]. It has also been shown to have a lower 
sensitivity and specificity for clinical outcomes than several alternative definitions 
[52]. 
In the thesis we used the “Houston criteria”, which specify that relapse is scored 
when the PSA level is 2 ng/ml greater than the nadir (defined as the lowest no rising 
value) [52, 56-58]. Relapse was scores at the time when the “2 ng/ml over nadir” 
was first observed. 
Because of the many shortcomings in the ASTRO definition, in 2006 a second 
Consensus Conference was sponsored by ASTRO and the Radiation Therapy 
Oncology Group (RTOG) in Phoenix, to revise the ASTRO definition. 
Recommendations of the RTOG-ASTRO Phoenix consensus conference [59], 
suggested the following guidelines for the use of PSA as a parameter of prognosis 
and efficacy of radiotherapy: 
1. A rise by 2 ng/ml or more above the nadir PSA be considered the standard 
definition for biochemical failure after  external beam radiotherapy (EBRT) 
with or without hormone therapy (HT) 
2. The date of failure be determined “at call” (not backdated) 
Thus the definition we have used is the current recommended method to define 
biochemical failure after radiation treatment for PC. 
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 Screening: 
The PSA test detects PC at an early stage in many cases. At present, data are not yet 
available from large, well-designed, randomizes trials to determine whether early 
detection is beneficial or harmful or has no effects. As a result, the optimal strategy 
for early detection with PSA testing remains unknown [39]. PSA screening is 
recommended by the American Urological Association and the American Cancer 
Society annually for all men 50 years or older. For men with a family history of PC 
or of African-American descent PSA testing should begin at age 40 years [45]. The 
Norwegian Urological Cancer Group (NUCG) and Health Authorities do not 
recommend PSA screening at the present point [60, 61]. However, a revision of the 
statement awaits the results from the ongoing screening trials and taking into 
consideration that it has now been documented that surgery is better than observation 
[62]. The guideline is based on the presumption that no therapy is effective in 
prostate cancer. 
The value of screening for PC in terms of lowering PC mortality is at present 
unproven. Two large studies [63, 64] address the issue and results are expected within 
the next few years. The decline in mortality observed in several countries the last 
years (Figure 2) may be related to “wildscreening” with PSA testing, better local 
therapy, or both. 
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2. Treatment of prostate cancer 
The selection of optimal treatment for men with localised PC is controversial. As 
there is still no randomised trial with sufficient power comparing the main treatment 
alternatives, there is little solid evidence showing one management strategy to be 
superior to another. The choice of treatment often depends on the personal conviction 
of the physician in charge of the patients [65]. 
Partin tables are constructed for general patient risk evaluation, and the tables have 
recently been updated. They represent risk estimation using the baseline PSA, clinical 
stage and Gleason score, based on the pathologic evaluation of 5079 surgically 
managed patients [66, 67]. The Kattan nomogram was developed to predict the 5-
years probability of treatment failure, defined as rising PSA level, among men with 
clinically localized PC treated with RP [68] or EBRT [69]. The RP nomograms was 
developed using clinical data and disease follow-up for 983 men with clinically 
localized PC, treated with RP. The clinical data included pre-treatment PSA, stage 
and biopsy Gleason score [68]. The nomograms for EBRT was based on clinical 
parameters of 1042 PC patients treated with three-dimensional conformal 
radiotherapy (3D-CRT), including stage, biopsy Gleason score, pre-treatment PSA, 
and whether neoadjuvant androgen deprivation therapy was administered, and the 
radiation dose delivered [69]. 
2.1 Radical Prostatectomy  
The surgical treatment of PC consists of RP, meaning the removal of the entire 
prostate gland between the urethra and the bladder, with resection of both seminal 
vesicles. Current surgical techniques include an open retropubic or perineal incision, 
and quite a number of centres are now gaining experience with laparoscopic radical 
prostatectomy [70]. Pelvic lymphadenectomy can be performed concurrently with 
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radical prostatectomy and is generally reserved for patients with higher risk of nodal 
involvement [71]. 
RP is widely used in the treatment of low to medium risk PC; the patients need to 
have a life expectancy of at least 10 years and absence of comorbidity. Survival is 
remarkable with 10 year’s cancer specific survival of 94-98 % [72, 73]. Long-term 
side effects may include erectile dysfunction (14-71%) and urinary incontinence (7 -
14%) [74-76]. The effect of surgery on potency seems to be age dependent [74]. 
Surgical experience has decreased the complication rates and improved cancer cure 
[77, 78]. 
RP is the only treatment for localized PC that has shown a cancer specific survival 
benefit when compared to watchful waiting (WW) in a prospective, randomized trial 
[62].  
2.2 External beam radiation therapy  
EBRT was introduced for PC as early as in the 1930s when Wiedmann reported 
palliation with low-energy orthovoltage treatment in patients with this disease [79]. 
This treatment was superseded in the early 1940s by introduction of hormone 
deprivation by Huggins and Hodges [79]. In the mid 1950s definitive external 
radiation of PC was introduced by Bagshaw who applied the linear accelerator 
technology and by George and Del Regato who used cobalt units [79]. Since then, the 
technological development in RT has been enormous. Besides, also the treatment 
techniques and the treated volumes have changes considerably over the years.  
Bagshaw [79] introduced large fields to encompass the pelvic lymph nodes (up to 50 
Gy) before completing treatment using smaller fields up to full dose.      
Early use of definitive EBRT for PC involved so-called two-dimensional (2D) 
radiotherapy, usually consisting of a single beam from one to four directions. Beam 
setups were usually quite simple; plans frequently consisted of opposing AP/PA or 
lateral fields or four field “boxes”. The introduction of 3D, or CT-based, planning 
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represented a major step forward because it became possible to take into account 
axial anatomy and complex tissue contours. While 3D planning allowed for accurate 
dose calculations, 3D-CRT first became available in the mid 1980s, and by the early 
1990s reports from several institutions supported the notion that compared with 
conventional therapy, rectal toxicity was lower than expected despite higher doses 
[80, 81].  
Radiation target volumes are defined according to the International Commission on 
Radiation Units and Measurements (ICRU) report 50 [82].  The Gross Tumor 
Volume (GTV) is defined as all known disease indicated by the planning CT or any 
other information. The Clinical Target Volume (CTV) is defined as the GTV and 
subclinical microscopic malignant disease. In PC, the entire prostate is usually 
considered the CTV. Finally, the Planning Target Volume (PTV) is the CTV plus a 
surrounding margin to account for the variability of treatment setup and the internal 
organ motion. The ICRU 62 report [83] provided guidelines and a framework for 
studies on internal motion and set-up variability for determination of treatment 
margins.  
EBRT remains a mainstay in the treatment of patients with PC. High radiation dose is 
important to eradicate all tumour cells. The improved technologies have improved the 
ability to dose-escalation to the prostate while sparing the volume of normal tissue 
(rectum and bladder) that receives clinically significant doses, resulting in a reduction 
in complication rates [84].  
A Scandinavian randomized phase III trial [85] has demonstrated a 10 % absolute 
survival benefit after a median follow up of 7.5 years, from addition of EBRT to HT, 
in patients with locally advanced PC . Absolute difference in cumulative incidence of 
PSA recurrence at 7 years was 53.5 %, indicating that with longer follow-up the 
survival benefit will further increase. 
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2.2.1 Intensity modulated radiation therapy (IMRT) 
IMRT is a refined CRT technique that produces highly individualised dose 
distributions, tailored to the anatomy of the specific patient. The clinical applications 
include conformal avoidance strategies aimed at reducing the radiation dose to organ 
at risk (OR) (rectum, small bowel and bladder) and hence normal tissue radiation 
toxicity, or radiation dose escalation to tumours with the goal of increased tumour 
control [86].  This is accomplished by using computer-controlled movement of the 
multileaf collimator (MLC), either by continuous movement during beam delivery 
(dynamic IMRT) or by step-wise leaf movement between the beam segments 
(segmental IMRT). The third conventional IMRT approach called intensity-
modulated arc therapy (IMAT) [87] or volumetric modulated arc therapy (VMAT), 
uses multiple irregular fields shaped with a conventional MLC during gantry rotation, 
in the latter also the dose rate is modulated during beam delivery [88-90].                                            
 Use of IMRT for pelvic irradiation in PC reduces normal tissue doses, improves 
target coverage, and has a promising toxicity profile [91].  
The use of IMRT is opening the way for concomitant delivery of different doses to 
different target volumes, e.g., combining two-phase treatment using integrated boost 
as well as local dose escalation, resulting in a shorter duration for the overall 
treatment time [92]. In October 2006 our institution moved into a Phase II IMRT 
study of a simultaneous integrated boost (SIB) for locally advanced PC patients, 
where we simultaneously treat both pelvic lymph nodes (with conventional 
fractionation, i.e., 2 Gy per fraction) combined with hypofractionated doses (2.4-2.7 
Gy per fraction) to the prostate and seminal vesicle, in a total of 25 fractions [93, 94].  
IMRT and inverse treatment planning have provided new methods to deliver 
nonuniform or shaped dose distribution. There is an increasing interest in integrating 
biological information into IMRT. New types of image can provide biological and 
mechanistic data, for example, MRI spectroscopy, single-photon emission CT 
(SPECT) and positron-emission tomography (PET), allowing for identification of the 
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cancer within the prostate gland, enabling “dose painting” to the tumour areas [95-
97]. Dose painting strives to tailor the dose inside the tumor to deliver the exact 
amount of radiation needed for eradication and challenges the dogma of dose 
homogeneity to the target [98]. 
2.2.2 Image-guided radiation therapy 
Organ motion is a challenge facing RT, recent studies have shown a significant organ 
motion of the prostate, both inter- and intrafraction [99]. Implanting three fiducial 
gold seed markers in the posterior and apical prostate gland is well tolerated and no 
significant seed migration occurs [100]. Daily electronic portal imaging of 
intraprostatic markers has been established as a reliable standard for online 
verification of treatment [101]. This allows for reduction of the PTV margins because 
of improved setup accuracy and reproducibility, and a corresponding lower dose to 
the ORs [102], it can also monitor volume change in the prostate that can occur over 
time due to hormone or RT [100].  
Helical Tomotherapy is another approach to image-guided radiotherapy. In the last 
years there has been a transition in radiation oncology from standard treatment 
planning and targeting methods to more advanced approaches based on significant 
improvements in imaging and treatment delivery [103]. The helical delivery permit to 
obtain highly tailored dose distribution with excellent coverage and homogeneity 
within different targets, especially in the case of concomitant boost delivery [104, 
105]. Dose delivery is performed by translating the patients in a continuously rotating 
fan beam modulated by a binary MLC [106]. A clinical study with Helical 
Tomotherapy in 35 patients with PC, pelvic lymph node where simultaneously 
treated combined with hypofractionated doses to the prostate and seminal vesicle or 
the prostatic bed only, in a total of 28 fractions,  showed very low incidence of acute 
Grade 2 and no acute Grade 3 toxicity [106]. However, longer follow up is necessary 
for final evaluation of this approach. 
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2.2.3 Acute and late toxicities after EBRT 
Along with improvement in cancer survival, the importance of toxicity measurements 
for cancer treatment is becoming increasingly important. In PC, there is a variety of 
different treatment options with the same outcome in terms of cure, but with different 
late toxicities. 
The therapeutic use of ionizing radiation is predicated on sparing normal tissue 
effects while attempting to achieve lethal effects on tumour cells. 
 Early normal-tissue response: Treatment related morbidity that occurs within 90 
days after the start of radiotherapy (Cox 1995). Early reaction is usually transient. 
The development of early effects in rapidly renewing tissue such as skin, 
gastrointestinal tract and the heamopoietic system is generally due to damage to 
parenchymal cells,  and α/β ratios tends to be high [107].         
Late normal-tissue response: Treatment related toxicity that occur or are persistent 90 
days or more from the start of radiotherapy. Late effects manifest months to years 
after acute effects heal, and often progress with time. Late effects can be expected in 
slowly proliferating tissues, such as lung, kidney, heart, liver and central nervous 
system, generally due to damage to connective-tissue cells, and α/β ratios tends to be 
low [107].         
Several authors have indicated a direct relationship between acute and late GI 
morbidity, independent of dose [108, 109]. This phenomenon, known as 
consequential late effect, is defined as a direct consequence of acute radiation 
response causing tissue damage, which eventually leads to late effects after a latent 
symptom-free interval [110, 111]. 
The RTOG developed the late RTOG toxicity criteria in 1981 and in 1985 the acute 
RTOG criteria as a complimentary scheme [112]. The National Cancer Institute 
developed standard toxicity criteria in 1990, but late effects were not considered. In 
1995 the LENT SOMA scoring system was introduced, with the acronym LENT 
referring to Late Effects in Normal Tissue and SOMA referring to Subjective, 
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Objective, Management and Analytic [113]. The Common Toxicity Criteria version 
1.0 (CTC v1.0) of 1983 was developed for chemotherapy-related adverse effects. It 
was upgraded and expanded in 1998, but CTC v2.0 was still focused on acute effects, 
including early radiation effects [114]. In 2003 a new version, CTCAE v3.0 
(Common Terminology Criteria for Adverse Events v3.0) was published which 
represents the first comprehensive multimodal grading system to include both acute 
and late effects of cancer treatment [115]. It is considered as a “dynamic” document 
and will be updated regularly as necessary.  Overall, this large activity underlines the 
importance of standardisation to improve the recording of toxicity. A therapeutic gain 
cannot be achieved without carefully balancing tumour cure and survival rates against 
morbidity. Development of standardized common toxicity criteria and a widespread 
adoption of these in clinical trials would be a major step forward for clinical cancer 
research [116].             
2.3 Brachytherapy 
There are two major methods of prostate brachytherapy, low dose rate (LDR) 
permanent seed implantation using iodine 125 (125I) or palladium 103 (103Pd) and 
high dose rate (HDR) temporary brachytherapy using iridium 192 (192Ir). The dose 
prescribed is usually 145 Gy for 125I and 125 Gy for 103Pd at the periphery of the 
target volume. The prescribed dose for HDR temporal brachytherapy is usually 10-15 
Gy/2 fractions in addition to 40-50 Gy delivered using EBRT [117-119] and maximal 
androgen blockade (MAB) [120].                                                                                                          
The American Brachytherapy Society has recommended brachytherapy monotherapy 
for patients with clinical stage T1c-T2a, serum PSA level of ≤  10 ng/ml, and a 
Gleason score of ≤  6, with the addition of  supplemental EBRT for all those with 
higher risk feature [121]. The prostate volume should be less than 50cm3, the patients 
should have a low urinary symptom score and a life expectancy of at least 5 years 
[118].  
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Factors that predict higher complication rates include prostate size at the time of 
treatment (larger than 50-60 cm3). The patient’s urinary symptom score before 
treatment (this is the most sensitive predictor of urinary morbidity), as well as recent 
transurethral resection of prostate (TURP) (being associated with a higher than usual 
risk of incontinence [117, 122]). Long term side effects are urethral stricture in 1.7-12 
%, proctitis in 2-11 % and approximately 30-53 % may become impotent [118, 123, 
124]. 
2.4 “Active surveillance” or “watchful waiting”                                        
In early PC, the choice of therapy is complex. The majority of newly diagnosed PC 
patients now have low risk T1c disease. Pathology studies have suggested that 16-19 
% of T1c cancers are insignificant [125, 126]. Patients with PC who fall into this 
category include men with a Gleason score ≤  6, a PSA of ≤  10 ng/ml and stage T1c 
or T2a disease [127]. As a result of stage migration because of PSA screening, the 
proportions of newly diagnosed patients who fall into the “favourable-risk” category 
has increased and now constitute 50 % to 60 % of patients [128]. Although patients 
with these characteristics have a much more favourable natural history and 
progression rate than those with a higher Gleason score or PSA, some of them still 
progress to advanced, incurable PC and death [129]. The main challenge in these 
patients is to identify the minority of patients with aggressive PC, and offer them 
curative treatment, while sparing the remainder the morbidity of unnecessary 
treatment [130]. A new promising option is active surveillance, which aims at 
individualised therapy by selecting only those men with progression and therefore 
significant cancer for curative therapy [131, 132]. However, this policy depends on 
active monitoring using PSA and repeated prostate biopsies and about one third will 
sooner or later need treatment [133]. Klotz reported on a cohort of 299 patients, in 
which 80 % was defined as low risk. At 8 years, the overall survival was 85 % and 
disease specific survival was 99 %. However, he concluded that WW is clearly 
appropriate for elderly PC patients with high rate of comorbidities. For low risk, 
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young, healthy patients, this study supports the feasibility of long-term, close 
monitoring with early intervention for those who exhibit rising PSA [131].      
Active surveillance for screening-detected, low volume cancer is based on the 
following 5 postulates [134]: 
1. PC screening results in the detection of PC that is not clinically significant in 
many patients (i.e. untreated, would not pose a threat to health). 
2. The patients who fall into this category can be identified with reasonable 
accuracy. 
3. There is no treatment that is minimal in terms of side effects and cost. 
4. Patients who are initially classified as low risk who reclassify over time as 
higher risk and are treated radically are still cured in most cases. 
5. The psychological burden of living with untreated cancer has less impact on 
quality of life than unnecessary but curative therapy. 
It is important to distinguished active surveillance from WW. WW involves 
observation with late treatment for those who develop symptoms of progressive 
disease [133]. It is appropriate for elderly PC patients with co morbidities or limited 
life expectancy. In the PSA era, few patients are willing to be managed with WW 
until metastatic disease develops [135].  
At present, there is no reliable individual clinical or pathologic factor that can 
differentiate an indolent tumour from an aggressive one [136]. 
2.5 Future prospects of radiation therapy 
During the last 20 years, the primary focus for technologic advancement in radiation 
oncology had been on improving the methods of dose delivery, for both maximum 
tumor control and minimum normal tissue toxicity [101]. The fast development of 
EBRT modalities is very promising, and more patients are now cured with RT. In the 
early to mid 2000s, functional and anatomic imaging began to be used to better define 
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the extent of disease for men with clinically localized PC. During the next 5 to 10 
years, better understanding of biology combined with functional and anatomic 
imaging will likely drive future advantage in radiotherapy for PC [101]. 
Proton therapy has been in clinical use since the 1970, the main rationale had been 
poor local disease control with conventional therapy, and the proximity of critical 
dose-limiting normal tissue, which is a bar to safe dose escalation using conventional 
photon RT [137]. A single proton beam has a low entrance dose, a maximal dose at a 
user-defined depth (the “Bragg peak”), and no exit dose. These characteristics make 
possible a substantial reduction in integral dose (i.e dose delivered to normal tissue), 
and a favourable dose-distribution over conformal therapy [138]. However the role of 
proton RT in the treatment of PC remain unclear because similar treatment results 
have been reported for modern photon techniques such as IMRT or stereotactic 
photon RT [139]. 
Carbon ion (C-ion) beam offer advantageous biological and physical properties in RT 
(inverse dose profile, Bragg peak) [140, 141] both improved dose distribution and 
probability of normal tissue complication will be minimized. They have a high 
relative biological effectiveness resulting from high linear energy transfer [142], the 
relative biological effectiveness value for C-ion is estimated to be about 3 times those 
of photons [143]. Clinical phase II studies of hypofractionated C-ion RT for PC have 
confirmed the effectiveness and safety of the treatment [143-145]. At the present time 
no conclusion can be draw concerning the utility of C-ions in the treatment of PC 
[146]. 
2.6 Hormone therapy  and chemotherapy 
Primary androgen deprivation therapy (ADT) may be employed with the goal of 
providing symptomatic control of PC for patients in whom definitive treatment with 
surgery or radiation is not possible or acceptable [71].  
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One rational for combining adjuvant hormones with definitive radiation is to decrease 
the volume of the prostate, which decreases the size of the treatment fields, which in 
turn potentially decreases toxicity to adjacent normal tissues. A second rationale for 
combining hormones and radiation is to improve the effectiveness of radiation [147]. 
The use of early ADT in combination with radiotherapy in patients with localized and 
locally advanced disease, has shown to delay disease progression and to improve 
overall survival (OS) [148-152]. The National Comprehensive Cancer Network 
(NCCN) recommends HT plus RT for patients with high-risk disease [153]. 
Neoadjuvant ADT before RP is not indicated today and should not be utilized outside 
a clinical research setting [154]. Timing of the institution of ADT for PC remains 
controversial, but there is a growing consensus that men with nodal disease at the 
time of RP have a survival benefit from immediate ADT [154-156]. 
ADT is the mainstay of treatment for recurrent metastatic PC (chemical or surgical 
castration). The response to treatment last for a median duration of 18-24 months. 
Most men become resistant to therapy and develop hormone refractory PC (HRPC) 
[157]. ADT provides important quality of life benefits, including reduction of bone 
pain, pathological fracture, spinal cord compression and ureteral obstruction. 
However, it is not clear whether there is an improvement in long-term survival [158]. 
Although no clear-cut guidelines have been established, there is a growing tendency 
to treat patients with recurrent PC with ADT at some point when PSA is rising, prior 
to symptom development [154]. Once all hormonal options have been exhausted, 
advanced disease can be considered to be truly hormone refractory, although 
luteinising hormone releasing hormone (LHRH) agonist therapy should be continued 
to avoid testosterone-induced accelerated progression [159]. 
Until recently, few options were available for men with HRPC. The aim of the 
chemotherapy is to prolong survival and improve well-being. In the late 90s two 
studies comparing mitoxantrone plus corticosteroids or corticosteroids alone for 
symptomatic HRPC, showed pain relive and improve quality of life more frequently 
with the combination arm than corticosteroids alone, but neither demonstrated an 
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improvement in survival [160, 161]. Consequently the Food and Drug Administration 
(FDA) approved the combination of mitoxantrone and corticosteroids for the 
treatment of symptomatic patients with HRPC [157]. 
Combination of vinorelbine and hydrocortisone versus hydrocortisone alone in 
randomised phase 3 study [162], showed an advance in the combination arm, in terms 
of six-month progression-free survival, PSA response and clinical benefit, but no 
improvement in survival. In a phase 3 trial comparing vinblastin with vinblastin plus 
estramustine, a statistically significant advantage in terms of time to progression and 
PSA response was found in favour of the combination arm, but not significant 
improvement in OS [163].   
Vinorelbine and hydrocortisone represents a valid alternative therapeutic option for 
the treatment of patients with HRPC, especially those who are not suitable for 
treatment with taxanes and/or mitoxantrone, or after taxane failure [162]. 
A phase 2 study with weekly docetaxel and prednisolone versus prednisolone (best 
supportive care) alone in HRPC patients was conducted in Norway [164], the study 
confirms the activity of weekly docetaxel in HRPC patients and indicated superiority 
in pain relief and quality of life assessment.   
In 2004, two large randomized phase 3 trials SWOG 99-16 [165] and TAX327 [166], 
where published. The SWOG 99-16 trial compared docetaxel plus estramustine with 
mitoxantrone plus prednisone. It showed advances in median OS and median time to 
progression in the docetaxel arm. The TAX327 trial had two schedules of docetaxel 
administered with prednisone were compared with mitoxantrone plus prednisone, the 
standard chemotherapy for HRPC. It showed a significant improvement in median 
OS for the group that received docetaxel every three weeks than for the mitoxantrone 
group, but not for the group that received weekly docetaxel. Overall, as compared 
with the mitoxantrone group, the docetaxel group had better pain control, better 
quality of life and more frequent PSA response, but at the cost of higher incidence of 
adverse effects.    
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In May 2004 the FDA approved docetaxel 75mg/m2 every 3 weeks plus prednisone, 
as front line therapy of HRPC [167]. It is reasonable to conclude that treatment with 
docetaxel plus prednisone administered every 3 week can be considered the treatment 
of choice in the first line in HRPC in fit patients. If the goal of treatment is palliation, 
weekly docetaxel therapy is justified. Mitoxantrone plus prednisone has become the 
de facto second-line regiment [157]. 
Even though HRPC remains incurable, it is not untreatable, today there are many 
phase 2 study ongoing focusing on antiangiogenic drugs in combination with 
chemotherapy [168].          
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3. Aims of the study 
The aims of the present thesis were: 
1. To analyse the effect of radiation dose escalation (cohorts of 64 Gy, 66 Gy 
and 70 Gy) on PSA failure, cancer specific survival (CSS) and OS in patients 
with prostate cancer (Papers I and II).  
2. To analyse the impact of radiation dose escalation and hormone treatment on 
PSA failure free survival (bNED), CSS and OS in prostate cancer patients 
according to risk group (Paper II). 
3. To investigate frequency of acute toxicity (gastrointestinal and genitourinary), 
the relation between acute toxicity and irradiated volume in the organs at risk 
(rectum and bladder) during three-dimensional conformal radiation therapy for 
prostate cancer (Paper III). 
4. To investigate the incidence, time course and relation to irradiated volumes of 
late toxicity after three-dimensional conformal radiation therapy for prostate 
cancer (Paper IV). 
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4. Patients and methods 
This chapter gives an overview of the patients series included and the methods 
applied to fulfil the aims of the study. More specific details can be found in the 
corresponding papers (Papers I-IV). 
4.1 Patients materials 
Time period        Patients numbers and treatment          Endpoint  
01.1990         
 
 
   
 
 
12.1999 
01.2000 
12.2000 
01.2001 
12.2001 
 
 
64 Gy (140 pas) 
HT: 47 % 
1990-1994
70 Gy (250 pas) 
HT: 100 % 
1997-2000
66 Gy (104 pas) 
HT: 84 % 
1994-1996
bNED, CSS and OS 
Clinical outcome 
 
 
Effect in risk groups 
70 Gy (115 pas) 
HT: 87 %
70 Gy (132 pas) 
HT: 86 %
Late toxicities   
(01.2000 – 12.2001) 
 
Acute toxicities 
(01.2001 -12.2001) 
Paper I and II 
Paper IV 
Paper 
III
 38 
This study included patients with localised and locally advanced prostate cancer (T1-
T4NxM0) that were offered EBRT, with or without androgen deprivation, between 
January 1990 and December 2001 at Haukeland University Hospital. 
In paper I-II, the study population (494 patients) included patients treated between 
January 1990 and December 1999. In this period the tumour dose was stepwise 
escalated from 64 Gy via 66 Gy to 70 Gy. After radiotherapy the patients were 
scheduled to be followed at the department of urology at the local hospital, or with 
the patient’s general practitioner. Annual reports were sent to the Department of 
Oncology, Haukeland University Hospital, reporting on clinical progression, adverse 
effects and death. All patients were followed to death or to May 5, 2004.  
PSA level was used as a surrogate endpoint for disease activity. We used the Houston 
method which specify that a relapse is scored when PSA is 2 ng/ml greater than the 
nadir PSA [56-59]. All patients with a rising PSA above this level were considered as 
having biochemical failures.  
In paper II we defined three risk groups, with patients in the low risk group having 
stage T1c disease, a pretreatment PSA level ≤ 10 ng/ml and a WHO Grade 1. In the 
intermediate risk group, patients had one or more of the following adverse factors: 
stage T2 disease, PSA > 10 ng/ml and ≤ 20 ng/ml and biopsy WHO Grade 2. Patients 
in the high-risk group had one or more of the following factors: stage T3 disease, PSA 
> 20 ng/ml and biopsy WHO Grade 3. 
In paper III, the study population (132 patients) included all patients treated from 
January to December 2001. In paper IV, the study population (247 patients) included 
all patients treated from January 2000 to December 2001. All these patients were 
prescribed a total dose of 70 Gy. Patients were stratified into three treatment groups 
according to T-stage, PSA and Gleason score:  
Group P: In patients with clinically organ-confined disease of stage T1c, PSA ≤ 10 
and Gleason score ≤ 7 (3+4 but not 4+3), the CTV encompassed the prostate only. 
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The patients received radiation to the prostate med wide margin to 50 Gy, followed 
by a 20 Gy boost to the prostate with narrow margin. 
Group PSV: Patients with clinically organ-confined disease of stage T1c with PSA > 
10 but ≤ 30 or Gleason score ≥ 7 (4+3 but not 3+4), as well as all patients with T2 
disease, received radiation to the prostate and seminal vesicles to 50 Gy, followed by 
a 20 Gy boost to the prostate only.  
Group MPF: In patients with stage T3 or N+ a larger volume was treated with 
modified pelvic fields to 50 Gy, followed by a reduced volume, which encompassed 
the prostate and seminal vesicle [148].  
In paper III, 26 patients (20 %) were in Group P, 86 patients (65 %) in Group PSV 
and 20 (15 %) in Group MPF. In paper IV, 48 patients (20 %) were in Group P, 154 
patients (62 %) in Group PSV and 45 (18 %) in Group MPF. All patients were seen 
for follow-up every 6 months during the first year and then annually thereafter. At 
each follow-up visit, late gastrointestinal (GI) and genitourinary (GU) morbidity was 
scored. 
Pre-radiotherapy diagnostic work up: The patients were staged by physical 
examination, PSA testing and isotope bone scan. For most patients a diagnostic 
transrectal ultrasound and computer tomography (CT) scan was also performed. 
Surgical lymph node staging and magnetic resonance imaging (MRI) were not 
routinely performed. In Papers I and II the primary tumour was clinically staged 
according to the 1992 TNM classification for PC [20] and in Papers III and IV 
according to the 1997 TNM classification for PC [18], but without grouping into 
subcategories (a, b, c). Histology was in the first part of the study based on WHO 
histological grading (302 patients) [22], later according to the Gleason scoring system 
(192 patients) [169].  As the treatment decision were based on the original WHO 
grading, we have used the original grading in the analyses. But in the uni-and 
multivariate analysis in Paper I and II, we converted Gleason score into WHO 
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grading: Gleason score 4-6 to well differentiated, Gleason score 7 to moderately 
differentiate and Gleason score 8-10 to poorly differentiated [170].   
4.2 Radiotherapy and hormonal therapy 
All patients underwent EBRT with individualised treatment planning, using high 
energy photons to a total tumour dose of 64 - 70 Gy, in 2 Gy fractions five days a 
week, over 6 - 7 weeks. Before 1995 the treatment plan was based on a diagnostic CT 
with adaptation to the patients contour at simulation, later all treatment plans were 
based on images from our dedicated CT scanner. Until 1995 we applied a four-field 
box technique (opposing anterior-posterior fields and two opposing lateral fields) 
with 2 cm uniform margins to 50 Gy before a boost with smaller margins were 
delivered using four fields or two lateral fields to a total dose of 64 Gy (Figure 5).  
 
Figure 5. Typical conventional definitive radiotherapy of prostate cancer using two opposing AP-PA fields (a), 
and two opposing lateral fields (b), as used 1990 - 1995. 
Field shaping with individually customised blocks was used occasionally in the first 
part of the study period, and routinely from 1994. In 1996, the use of customised 
blocks was substituted by MLC. In addition, the dose was increased, first to a total 
dose of 66 Gy, and then further increased to 70 Gy in 1997 (Figure 6). A dose of 50 
Gy was given during a five-week period to a large volume, while an additional 20 Gy 
was given over the last two weeks to a smaller target volume (the boost volume). The 
dose was prescribed as the mean dose to the internal target volume (ITV). 
 41
 
 
Figure 6. Conformal radiotherapy (CRT) of prostate cancer, AP-PA field with vesicular seminalis included (a) 
and lateral field (b), used 1996 – 2001. 
Neoadjuvant and adjuvant HT was used in many patients. In the first part of the study 
period LHRH agonist was used to downstage tumours before RT for an average of 4-
6 months. Later patients presenting with more advanced tumours in the prostate 
(stage ≥ T2a, PSA > 10 or Gleason score ≥ 7 [4+3 but not 3+4]) were candidates for a 
6-months course of LHRH agonist and antiandrogen (MAB). The endocrine 
treatments started 3-4 months before CRT and were administered to reduce the 
prostate volume and thereby reduce the dose of radiation delivered to the rectum and 
bladder [171-178]. The HT continued during and at least one month after the start of 
RT, to exploit the possible synergy between HT and radiation [179].  
4.3   Scoring of acute and late side effects 
In Paper III symptoms of acute GI, anal and GU toxicity induced by the radiotherapy 
was recorded. The RTOG acute toxicity scoring system was used to grade GI and GU 
toxicity during the course of treatment [112]. Anal symptoms were scored according 
to the modified scoring system of Koper et al. [180] (Table 3). In general, GI or GU 
symptoms that needed medical prescriptions were scored at least as Grade 2 toxicity. 
Patients were seen before and at least two times during treatment (week two and six), 
or more frequently if required.                      
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In Paper IV symptoms of late GI and GU toxicity induced by the RT was 
recorded. The RTOG scoring system [112] was used to grade late GI and GU toxicity 
from 3 months after treatment and up to 5 years after treatment. Late complications 
were defined as side effects developing more than 90 days after the completion of 
irradiation or those that started prior to and persisted for longer than 90 days after 
completion of treatment. For each symptom, the maximum recorded grade was 
defined as the grade of late toxicity, even when the side effect later declined. When 
patients were diagnosed with a locoregional recurrence, further assessment of 
complications was omitted from that moment on, as distinction between treatment-
related or recurrence-related symptoms can be difficult. Patients with biochemical 
relapse or distant metastases only were not censored from the analysis. 
Table 3. The modified RTOG acute scoring system 
 
*ad modum Koper et al. [180] and RTOG [112] 
4.4 Dose-Volume Histograms (DVH) 
In Papers III and IV the DVHs were calculated for the total treatment plan (to 70 Gy) 
for both ORs, e.g. the bladder and rectum, to investigate a possible correlation with 
observed toxicity (acute and late toxicity). Since both the rectum and bladder were 
defined as solid organs, the DVHs contained the dose to the whole of this volume 
(i.e., including contents). From the DVHs of each patient, the mean dose and the 
lanAyraniruotineGmutcergnidulcniIGrewoLedarG *
0 No change No change No change
1 Increased frequency or change in quality of
bowel habits not requring medication/rectal
discomfort not requiring analgesics.
Frequency of urination or nocturia twice pre-
treatment habit/dysuria, urgency not requiring
medication
Discomfort or pain not
requiring analgesics
2 Diarrhea requiring parasympatholytic
drugs/mucoous discharge not necessitating
sanitary pads/rectal or abdominal pain requiring
analgesics.
Frequency of urination or nocturia that is less
frequent than every hour. Dysuria, urgency,
bladder spasm requiring local anesthetic
Discomfort or pain
requiring analgesics
3 Diarrhea requiring parental support/serve
mucous or blood discharge necessitating sanitary
pads/abdominal distention
Frequency with urgency and nocturia hourly or
more frequently/dysuria, pelvis pain or bladder
spasm requiring regular, frequent narcotic/gross
hematuria
Discomfort or pain
requiring narcotics
4 Acute or subacute obstruction, ﬁstula or
perforation; GI bleeding requiring transfusion;
abdominal pain or tenesmus requiring tube
decompression or bowel diversion
Hematuria requiring transfusion/acute bladder
obstruction not secondary to clot passage,
ulceration or necrosis
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volume fraction above dose levels from 0 to 75 Gy in steps of 1 Gy were derived 
[181]. 
4.5 Statistics 
In Paper I, the primary endpoint was CSS, with OS and biochemical failure (BF) 
being secondary endpoints. The time to the relevant events was measured from the 
start of RT, analysed by Kaplan-Meier plots and assessed by the log-rank test [182]. 
Differences between groups were analysed by Kaplan-Meier plots and tested for 
statistical significance, initially using the log-rank test while Cox regression was used 
for univariate analyses of continuous covariates. Multivariate analysis was conducted 
using the Cox proportional hazard regression model. The statistical significance of 
the variables entered into the multivariate analysis was assessed using likelihood ratio 
tests.                                                                                                                                                        
In Paper II, the primary endpoint was CSS, with OS and bNED being secondary 
endpoints. The time to the relevant events was measured from the start of radiation 
therapy, analysed by the Kaplan-Meier method and assessed by the log-rank test as 
well as the multivariate Cox regression models.  
In Paper III, we evaluated the differences between treatments groups, testing the 
effect of co-morbidity on toxicity and effect of volume on acute toxicity with the 
Jonckheere-Terpstra test. To evaluate the differences between groups for the median 
DVH, one-way ANOVA with Scheffé post hoc analysis was used (the non-parametic 
version were seen to give the same results). A permutation test (using StatXact 5) was 
performed to evaluate the difference in relative DVH parameters between patients 
with Grade 0+1 vs. Grade 2 or higher morbidity. The effect of various treatment and 
background variables on acute toxicity was tested by logistic regression. In the DVH 
analyses, the significance of differences between the groups was tested by ANOVA 
and the Kruskal-Wallis-test. The effects of including each DVH variable in our 
logistic regression models were evaluated using the crude correlation measure of 
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predictive power introduced by Zheng and Agresti [183] and their p-values based on 
the likelihood ratio test [181].   
In Paper IV, comparison of patient characteristics between treatment groups was done 
using exact chi-square tests and one-way analysis of variance (ANOVA) for 
categorical and continuous variables, respectively. Changes of ≥ Grade 2 GI and GU 
morbidity during follow-up were analysed by population average logistic regression 
models adjusted for treatment groups. Time-adjusted actuarial incidence of ≥ Grade 2 
GI and GU morbidity were compared using Kaplan–Meier analysis with log-rank 
tests, with confidence intervals based on the log-log transformation. A multivariate 
analysis was performed using the Cox proportional hazard model. 
 To evaluate the differences in relative DVH parameter between patients and 
the effect of various treatment and background variables on late toxicity, we used the 
same methods as in Paper III. 
Finally in Paper IV, complication atlases [184] were constructed. These atlases are 
summaries of both the DVH and clinical complication data for all patients, in the 
form of a 2D map with the same axes as the DVH. Each grid point in the map 
contains both the number of patients with complication whose integral DVH passes 
above this specific grid point and the total number of patients in the study who also 
have an integral DVH passing above this point [184]. Grid point (0,0) thus contains 
the total number of complications and the total numbers of patients whereas in the 
grid points corresponding to the higher dose and volume combinations, progressively 
less patients are eligible for assessment of side effects. In this part of the analysis we 
applied the GU morbidity at least Grade 2 at 5 years, whereas for GI we used the 
maximum morbidity at least Grade 2 throughout the 5 years, because of only 3 events 
at 5 years follow-up. 
All referred p-values were derived from two-side test when appropriate. A p-level of 
0.05 was regarded as statically significant. We used the statistical software SPSS 
(versions 11, 12, 13 and 14, SPSS Inc., Chicago, USA) (in Papers I-IV), R (The R 
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Foundation for Statistical Computing, Vienna, Austria) [185] (in Papers II-IV) and 
StatXact (version 5 and 7, Cytel Software, Cambridge, MA, USA) (in Paper III and 
IV). 
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5. Summary of the results 
5.1 Paper I 
Radiation dose escalation combined with hormone therapy improves outcome in 
localised prostate cancer. 
 
In this first paper we presented the impact of systematic radiation dose escalation – 
from 64 Gy via 66 Gy to 70 Gy, on the outcome after radiation therapy alone or 
combined with HT in a series of 494 patients with T1-3NxM0 prostate cancer treated 
during 1990-1999. 
Of the 494 patients, 175 (35 %) had PSA failure at a median interval of 29 months, 
the 5 years OS and CSS rates were 85 % and 92 %, respectively. After a median of 
68 months 360 patients were alive, 340 of these patients without signs of progression.  
Prognostic factors for PSA failure, OS and CSS were investigated using multivariate 
analysis. T stage, pre-treatment PSA, grade, radiation dose and HT were found to be 
independent predictors of PSA failure. T stage, grade and HT were also independent 
predictors of both OS and CSS, while radiation dose was a significant predictor for 
OS and indicated a trend (p=0.07) for CSS. 
A dose of 70 Gy combined with hormonal treatment improves PSA failure free 
survival and OS in localised prostate cancer compared with doses of 64-66 Gy. 
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5.2 Paper II 
Outcome in intermediate or high risk prostate cancer patients receiving radiation dose 
and hormone therapy. 
 
In this paper we analysed the impact of radiation dose escalation and HT according to 
risk groups, in the same series as in Paper I. The patients were divided into three risk 
groups, where the low risk group (stage T1c, pretreatment PSA level ≤ 10 ng/ml, 
WHO Grade 1) included 26 patients, the intermediate risk group (either stage T2, 
PSA 10.1 - 20 ng/ml or WHO Grade 2) comprised 149 patients whereas the high-risk 
group (either stage T3, PSA > 20 ng/ml or WHO Grade 3) included 319 patients.   
In the intermediate risk group, the 5-years bNED rate was 92 %, 69 % and 61 % after 
a radiation dose of 70 Gy, 66 Gy or 64 Gy, respectively (p<0.001). In the high-risk 
group, the 5-year bNED rate was 79 %, 69 % and 34 % for the same dose levels 
(p<0.001). The 5-years CSS rates were not significantly different between the dose 
levels in the intermediate risk group while for the high-risk group it was 93 %, 92 % 
and 80 % for the three dose levels (p<0.001). Risk group and radiation doses were 
independent predictors of bNED, CSS and OS, for bNED also hormone treatment 
was independent predictors. 
From these findings we concluded that radiation dose is important for the outcome in 
intermediate and high risk prostate cancer patients. 
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5.3 Paper III 
Acute morbidity related to treatment volume during 3D- conformal radiation therapy 
for prostate cancer. 
 
In this paper we investigated the acute toxicity after radiotherapy for prostate cancer. 
From January to December 2001, 132 prostate cancer patients received a target dose 
of 70 Gy using 3-D CRT. Twenty-six patients (20 %) received irradiation to the 
prostate only (Group P), 86 patients (65 %) had field arrangements encompassing the 
prostate and seminal vesicles (Group PSV) while 20 (15 %) received modified pelvic 
fields (Group MPF). Acute toxicity according to the RTOG scoring system was 
prospectively recorded throughout the course of treatment.  
Overall, radiation was well tolerated with 11 %, 16 % and 35 % Grade 2 GI toxicity 
and 19 %, 34 % and 35 % Grade 2 or higher GU toxicity in Groups P, PSV and MPF, 
respectively. In univariate and multivariate analyses treatment group was a significant 
predictor for Grade 2 or higher acute toxicity. In multivariate logistic regression, the 
rectum DVH parameters were correlated to the incidence of acute Grade 2 GI 
toxicity, with the fractional volumes receiving more than 37-40 Gy and above 70 Gy 
showing the statistically strongest correlation. The fractional bladder volume 
receiving more than 14-27 Gy showed the statistically strongest correlation with 
acute GU toxicity. 
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5.4 Paper IV 
Late gastrointestinal morbidity after 3D- conformal radiation therapy for prostate 
cancer fades with time in contrast to genitourinary morbidity. 
 
In this paper we investigated the late toxicity after radiotherapy for prostate cancer. 
From January 2000 to December 2001, 247 prostate cancer patients received a target 
dose of 70 Gy using 3-D CRT. Forty-eight patients (20 %) received irradiation to the 
prostate only (Group P), 154 patients (62 %) to the prostate and seminal vesicles 
(Group PSV) while 45 (18 %) received modified pelvic fields (Group MPF). 
Androgen deprivation was given to 86 % of the patients. The median follow-up time 
was 62 months. Late GI and GU toxicity were recorded according to the RTOG 
scoring system.  
We observed 9 %, 7 % and 25 % Grade ≥ 2 GI toxicity and 36 %, 30 % and 21 % ≥  
2 GU toxicity in Groups P, PSV and MPF, respectively. In multivariate analyses age 
and treatment groups were independent predictors for the incidence of late Grade ≥  2 
GI toxicity, whereas age and urinary symptom before treatment were independent 
predictors for late Grade ≥  2 GU toxicity. Acute side effects predicted for late 
effects. The rectum DVH parameters correlated to the incidence of late Grade ≥  2 GI 
toxicity, especially the fractional volume receiving more than 40–43 Gy. The side 
effects tended to decrease with time. At 5 years follow-up, the rate of Grade 2 late GI 
toxicity was only 1 % and Grade ≥ 2 GU toxicity 11 %. 
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6. General discussion 
6.1 Survival analyses (Papers I and II) 
In the time period (1990-1999) we systematically increased the radiation dose -  in 
accordance with other centres -  from 64 Gy [186] via 66 Gy [187] to 70 Gy. Our 
results confirm that the two lowest doses yielded suboptimal tumour control [188]. 
Higher radiation doses can be used safely and particularly for localised tumours in the 
high-risk group have doses in the range of 74 – 81 Gy improved the tumour control 
rate [189, 190]. 
In the literature PC patients are often divided into three risk groups [127] - low, 
intermediate and high risk - in accordance to T stage, PSA and Gleason score. In our 
material we used this classification with modification because in our institution T 
stage was classified T1c, T2 and T3 and we only had grade but not Gleason score for 
the patients included in the first part of the study. 
Biochemical PSA failure is widely used as a surrogate endpoint for disease activity in 
PC, with various definitions being applied. Some authors have, however, not found 
an association [46] or questioned its relationship with increasing mortality [191]. The 
ASCO definition [49] was the most widely used definition of PSA failure but it had 
some problematic aspects; it performed poorly in patients undergoing hormone 
therapy and backdating biased the Kaplan-Meier estimates of event-free survival. We 
therefore used the “Houston criteria” were PSA relapse is scored when PSA is 2 
ng/ml greater than nadir [192], this definition is probably not affected by the use of 
hormones or follow-up length [58]. This method is the current recommended method 
to define biochemical failure after RT for PC [59]. 
In a previous study [193-195], the effect of radiation dose on relapse-free survival 
and overall mortality disappeared when year of treatment was included in the model. 
This finding indicates a more favourable presentation of localized PC in current years 
 51
that is not necessarily reflected in the patients PSA level or Gleason score. This 
phenomenon is probably related to a combination of many factors, such as  PSA 
screening, possibly also to changing cancer biology, but more likely to increased 
physician and patients’ awareness leading to more aggressive biopsies detecting of 
earlier presentation of the cancer [194, 195]. In our cohorts, on the other hand, year of 
treatment was not a significant factor for survival, while radiation dose remained a 
significant factor in the Cox model. The improved outcome after higher radiation 
dose can therefore hardly only reflect a better case mix alone. We have also analysed 
the data by consecutive time periods, excluding dose as this also reflects the time 
period.  Unfortunately we can not present a randomized study where period of 
treatment can be separately analysed in a model containing also the dose. We can 
therefore not exclude that stage migration contribute to our findings as there is 
several significant differences between the groups. However, as multivariate Cox 
regression represents a scientific approach to weight for the unbalanced factors, the 
results indicate that dose is an important factor for outcome for patients treated by 
radiation therapy combined with hormone suppression. 
In our cohort 81 % of the patients had adjuvant/neoadjuvant hormone treatment 
(mostly short-term). The addition of HT improved the effect of the lowest dose, 64 
Gy, but we unfortunately cannot assess its role at the highest dose level as most 
patients had started with hormones at the time of referral. There is now general 
acceptance for addition of long-term (3 years) hormonal suppression for locally 
advanced and high risk prostate cancer [149, 151, 196-198], but short-term (≤  6 
months) HT can not substitute for radiation dose in high risk patients [199]. Short-
term hormone therapy was given to most patients in the current series in order to 
maximise the effect of radiation. It is of interest that the dose used in D’Amico’s 
study [151] in T1b-2b patients with PSA >10 ng/ml or Gleason score at least 7 (range 
7-10) was 70 Gy with 6 months HT was the same as used in our study. Our current 
data seems therefore to confirm the excellent results in the combined arm by the 
American study. 
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6.2 Acute and late side effects of radiotherapy (Paper III 
and IV) 
In the recent years there has been an increased focus on acute and late toxicity after 
radiotherapy for PC. As PC patients have a potentially long survival, assessment of 
late toxicity is of major importance. The basis of CRT is that there is a dose response 
relationship for tumor control and that there are dose/volume response relationships 
for the involved normal tissues. The dose and volume response of normal tissue in                              
general is such that irradiating a smaller volume to a higher dose is possible within 
generally accepted limits of complications [200, 201]. The most important dose-
limiting ORs in RT of PC are the rectum and the bladder.  
In Paper III we presented acute radiation toxicity and in Paper IV late radiation 
toxicity data after CRT for PC, treating different volumes according to the tumour 
stage and documented risk factors. Overall the acute GI toxicity remained very 
favourable for Groups P and PSV, with 11 % and 16 % Grade 2 toxicity respectively, 
but there was only a trend towards higher Grade 2 toxicity (35 %) observed in Group 
MPF (p=0.06). We had no late Grade 3 GI or higher toxicity. The rectum dose in the 
three groups were clearly different, e.g. the median dose was 43 Gy and 46 Gy in 
Group P and PSV vs. 62 Gy in MPF, being a likely explanation for the difference in 
toxicity. However, it should be mentioned that the RTOG acute GI toxicity scoring 
system does not strictly discriminate between small bowel and rectal toxicity. And 
according to Koper et al. [180], anal toxicity also contribute to the GI toxicity. The 
low anal toxicity being reported in our study indicates a low anal radiation dose with 
our treatment technique.  
Most patients in our series had no or only Grade 1 late GI toxicity; Grade 2 late GI 
toxicity was observed in 10 % of the patients. We had no Grade 3 GI toxicity and 
only one Grade 4 GI and GU toxicity was observed in a patient in group PSV who 
had hemochromatosis. The GI toxicity remained very favourable for Groups P and 
PSV, with only 8 % Grade 2 toxicity or higher observed in both groups. There was, 
 53
however, significantly higher Grade 2 toxicity (25 %) observed in Group MPF (p = 
0.001).  
It is generally believed that late toxicity is permanent and may be progressive in 
severity. In contrast, our data show that most of the late Grade 2 GI toxicity was 
reversible. At 5 years, only 3 patients had still Grade 2 late GI toxicity (1 %). The 5-
year actuarial incidence of developing late Grade ≥  2 GI toxicity was 10 %. The 
median time to presentation was 13 months, with a further increase in incidence 
during the first 3 years after which the incidence stabilised. Others have reported that 
symptom levels may improve or resolve after Grade 2, but worse symptom levels 
after longer follow-up periods have also been reported [202-204]. Of interest is that 
Denham and co workers [205] indicated that patients who experienced little or no 
acute proctitis developed late symptoms that almost entirely resolved within 3 years 
of therapy. However, patients who experienced moderate or severe acute proctitis 
endured more prolonged late symptoms.   
In our institution we now use IMRT to tread locally advanced PC patients (group 
MPF). A recent study on this regimen showed 28 % acute Grade 2 GI toxicity and 
only 5 % late Grade 2 GI toxicity with a 12 months median follow-up [91]. 
It has been suggested that urethral mucositis and oedema within the prostate cause 
most of the urinary symptoms. This assumption is supported by the nature of the 
symptoms (frequency, urgency) as well as the particularly low incidence of acute GU 
toxicity in patients treated with 3D-CRT after radical prostatectomy [206]. The 
finding that use of IMRT for prostate cancer reduces rectal toxicity but not bladder 
toxicity despite reduced dose to the bladder [207] further supports the notion that 
most of the acute GU toxicity is caused by RT effects on the urethra within the 
prostate rather than in the bladder. According to this view, it seems unlikely that GU 
symptoms can be avoided when irradiating the whole prostate and thus including a 
segment of the urethra. In agreement with this, the differences in acute GU toxicity 
between the treatment groups in this series were less pronounced than the differences 
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in acute GI toxicity, despite considerable differences in the DVH and the DVH 
parameters also for the bladder.  
Bladder doses with our technique were relatively high, but there was still only 2 % 
acute Grade 3 GU toxicity rate in our material, in accordance with previous 3D-CRT 
series for prostate cancer, showing a 0-3 % incidence of acute grade 3 and 4 GU 
toxicity [180, 208-210]. We found a statistically significant difference between 
patients with Grade 0-1 vs Grade 2-3 acute GU toxicity for low doses only, but 
Valicenti et al. [211] found that the fraction of the bladder (≤ 30 % vs. > 30 %) 
receiving more than the prescription dose (68.4 Gy to 79.2Gy) were a significant 
predictor for acute GU toxicity. They also showed that men with poor baseline 
urinary function who were given HT had a significantly increased risk of acute GU 
toxicity. 
In our data analysis, late GU toxicity ≥ Grade 2 was not significantly different 
between the three treatments groups (p = 0, 95), despite differences in irradiated 
volume. This finding agrees with the study of Dearnaley [212].  
As reported in other studies, the rate of late GU toxicity for these patients continued 
to increase with time for at least five years [213, 214]. In our cohort the 5-year 
actuarial incidence of developing late Grade ≥ 2 GU toxicity was 29 % and median 
time 14.5 months.  Furthermore two-third of late Grade 2 GU toxicity is reversible: at 
5 years only 23 (10.6 %) patients had late Grade ≥ 2 GU toxicity. De Meerleer and 
colleagues similarly showed that 81 % of late Grade 2 GU toxicity was transient, 
except for incontinence, from which only 1 patient recovered [204]. 
With regard to reliable DVH data, rectum and bladder present special problems 
because they are both hollow and tend to have temporal variations in size, shape and 
position due to difference in filling [215-217]. The rectum and bladder DVHs based 
on the planning scan only may therefore not be fully representative for all of the daily 
treatment sessions, confounding the correlation between DVH parameters and 
toxicity. Still, it seems reasonable to assume that DVHs of the organ with content are 
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less sensitive to organ motion than DVHs of the wall or surface only [217-219]. 
Several investigators have reported that the volume of normal tissue exposed to 
higher radiation dose levels may represent the most significant factor affecting the 
development of late Grade 2 toxicity [220, 221]. 
Jackson et al. [181] found that late rectal bleeding correlates with the volume 
receiving doses above 70 Gy, but reported also a correlation between bleeding and 
the volume exposed to intermediate doses (40-50 Gy). This possibly indicates that 
when high-dose region are surrounded by extensive volumes receiving intermediate 
doses, the ability of this surrounding tissue to aid in the repair of a central injury may 
be impaired. Paper III confirms these findings, with a similar correlation between 
acute Grade 2 GI toxicity and the relative rectal volume receiving high (above 70 Gy) 
and intermediate doses (37-44 Gy). We found a similar correlation between late 
Grade ≥  2 GI toxicity and the relative rectal volume receiving intermediate (40 – 43 
Gy) and low doses (7 – 8 Gy). At highest dose levels (71 – 74 Gy) the correlation 
approached but did not reach statistical significance. Al-Albany and co workers [222] 
found that the risk of fecal leakage and urgency correlated with volumes of rectum 
receiving doses in the interval 25-42 Gy, but no association with blood and mucus in 
stools. 
The correlation between bladder DVH parameters and bladder toxicity (Grade 0+1 
vs. Grade 2+3) found for doses in the range 14-27 Gy and the difference found for 
fractional bladder volumes receiving more than 20 Gy were in general also slightly 
weaker than the corresponding correlations found for the rectum. Its biological 
explanation is uncertain, but it probably reflects a RT side effect linked to the whole 
(or most) of the bladder, e.g. reduced elasticity.  
Several authors have indicated a direct relationship between acute and late GI 
toxicity, independent of dose [109]. This phenomenon, known as a consequential late 
effect, is a direct consequence of acute radiation response causing tissue damage, 
which eventually leads to late toxicity after a latent symptom-free interval [110, 111, 
205]. In our study Cox multivariate analysis revealed acute toxicity to be an 
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independent factor when compared with late toxicity ≥ Grade 1 GI and GU. Acute 
rectal toxicity (p = 0.001) was the only independent predictor for the incidence of late 
Grade ≥ 1 GI toxicity and acute GU toxicity (p = 0.003) was the only independent 
predictor for the incidence of late Grade ≥ 1 GU toxicity. Others have also shown that 
both acute GI and GU toxicity were significantly related to their corresponding late 
injuries [84, 213, 223]. As late toxicity is partly a direct result of acute toxicity, it 
may be possible to limit late toxicity by limiting acute toxicity.  
6.3  Ongoing and future research 
The appropriate dose to cure early PC is still under investigation as 3D-CRT and 
IMRT dose escalation studies have provided strong evidence for radical treatment of 
early PC with doses > 72 Gy. These doses can be safely delivered with no increase in 
GI toxicities. 
From September 2005 we have used IMRT to treat high risk patients (Group MPF), 
with the RT course consisting of a initial IMRT plan delivering 50 Gy to PTV1 
(prostate, seminal vesicles, and lymph nodes with margin) (Figure 7) followed by a 
four-field CRT plan delivering 20 Gy to PTV2 (prostate and seminal vesicle with 
margin). Our early experiences suggest that IMRT reduces the dose to important ORs 
such as the intestine, bladder, and rectum when treating pelvic lymph nodes, while 
also improving target coverage. Clinical outcomes observed thus far are also 
promising, with a very low GI toxicity [91]. 
In October 2006 we moved into a Phase II IMRT study of a SIB for locally advanced 
PC patients, where we simultaneously treated pelvic lymph nodes (with conventional 
fractionation, i.e., 2 Gy per fraction) combined with hypofractionated doses (2.4-2.7 
Gy per fraction) to the prostate and seminal vesicle, in a total of 25 fractions. Gold 
fiducials inserted into the prostate are used for daily on-line target localisation, 
allowing for a considerable margin reduction. All patients start with endocrine 
therapy 3 months pre-RT with LHRH agonist and minimum 4 weeks with 
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antiandrogen, to exploit the reduction of the prostate volume, and continued with 
LHRH agonist 24 months after the start of RT. The aim is to include 100 patients into 
this study – currently 85 patients are included - with the primary endpoint being 
clinical and biochemical control after 5 years. Secondary aims are late GU and GI 
side effects and local control after 5 years.  
 
 
Figure 7.  Intensity modulated radiation therapy (IMRT) plan for prostate cancer, anterior view (a) and lateral 
view (b), current standard 
  Treatment of prostate cancer using radiotherapy can induce disturbance in a patient’s 
quality of life (QoL) and urinary and intestinal function. We intend to compare the 
difference between the treatment group and changes over time. 
From January 2000 to December 2001, a total of 247 patients with prostate cancer 
were treated with curative intent by using conformal radiation therapy to 70 Gy. 
Forty-eight patients (20 %) received irradiation to the prostate only (Group P), 154 
patients (62 %) received irradiation to the prostate and seminal vesicles (Group PSV), 
and 45 patients (18 %) received modified pelvic fields (Group MPF). 
Cancer specific QoL was evaluated with European Organization for Research and 
Treatment of Cancer’s QLQ-C30 formula, it is a questionnaire developed for the 
measurement of quality of life in cancer patients in clinical trial [224]. PC specific 
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QoL (urinary, intestinal and sexual function) was evaluated with a validated symptom 
specific self-assessment questionnaire, QUFW94/99© [225]. 
The patients answered the first questionnaire before treatment and then under 
treatment (132 patients treated in 2001).  All the patients answered the questionnaire 
6, 12, 24, 36, 42 and 60 months after the completion of treatment. 
This project will be evaluated when the thesis is completed. 
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7. Conclusions 
The current thesis consists of four papers addressing different aspect of RT for PC. In 
Paper I and II, dose response is analysed for all patients together and in subgroups 
according to risk assessment. In Paper III and IV, acute and late side effects, 
respectively, were prospectively assessed in patients treated at the same dose level as 
the highest dose level in Paper I and II.  
For the whole group receiving external beam radiotherapy (64 Gy, 66 Gy and 70 Gy) 
with or without hormonal treatment, 35 % has PSA failure at a median interval of 29 
months, with the 5 years OS and CSS rates being 85 % and 92 %, respectively. A 
dose of 70 Gy combined with hormonal treatment improved PSA failure free survival 
and OS in localised PC compared with doses of 64-66 Gy, while only a trend for 
CSS, probably due to low actual deaths from PC. 
When analysed in risk groups (low risk, intermediate risk and high risk group), higher 
radiation dose was found to be important for PSA failure and CSS in high risk PC 
patients, however, in the intermediate risk group the effect was only demonstrated on 
bNED. 
3D-CRT radiation therapy for PC to 70 Gy was well tolerated. Only two of the 132 
patients in the cohort experienced acute bladder toxicity Grade 3, none had Grade 3 
rectal toxicity. Uni- and multivariate analyses indicated that the volume treated was a 
significant factor for the incidence of Grade 2 or higher acute morbidity.   
 Late GI morbidity was low and faded with time, with only 1 % late Grade 2 GI 
morbidity at 5 years. GU morbidity was stable with time, with 11 % late Grade ≥ 2 
GU morbidity at 5 years. GU morbidity did not vary with treatment groups which 
probably reflected the fact that the urethra was included in all fields. Acute side 
effects predicted for late effects. 
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9.  Errata 
Paper I, page 456, Table I: overhead, “Group 2 (6 Gy)” should be: “Group 2 (66 Gy)”  
Paper III, page 45, second last sentence: it should be reference 19 but not 21 
Paper III, page 46, Table 2: it should be reference 24 and 6 but not 19 and 18 
Paper III, page 47, sixth paragraph: “… fractional volumes between 21-224 Gy.” 
Should be: “….fractional volumes between 21-24 Gy.” 
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                                                                                             Pasient no: ______ 
                                                             
 
 
REGISTRERINGSSKJEMA FOR AKUTTE EFFEKTER ETTER  
STRÅLEBEHANDLING AV PROSTATAKREFT. 
 
 
 
 
NAVN:____________________________              FØDT:____________________________ 
 
HENVISNINGSDATO:______________         DIAGNOSEDATO:_________________________ 
 
TIDLIGERE SYKDOMMER ( 0 - 7 ):____________ 
( 0 ingen, 1 DM, 2 hypertensjon, 3 hjerte sykdom, 4 tarm sykdom, 5 claudicatio(gen. art. scl. sykdom), 6 blære 
kreft, 7 annet ) 
 
Bruker statiner (JA/NEI): __________ 
               
       
KLINISK UTREDNING:  
  
SYMPTOMER : ____________________ 
PROSTATA BIOPSI ( JA / NEI ): ______________            DATO: _____________________   
TUR-P ( JA / NEI ): ________                     HVIS JA, HVILKEN ÅR: ___________________   
CT / MR ( JA / NEI ): ____________             ULTRALYD ( JA / NEI ): _________ 
STAGING LAPAROTOMI ( JA / NEI ): ________ 
SCINTIGRAFI ( JA / NEI ): ______ 
PSA(dato): ________               TNM: _____________          GLEASON: ______________   
PSA(før start av behandling/dato): ___________ 
 
 
BEHANDLING:     
 
 
 
HORMON BEHANDLING ( JA / NEI ): ________ 
TAB ( start ): ________________                        TAB ( slutt ): ____________________   
TYPE ANTIANDROGEN: _______________________ 
TYPE LHRH ANALOGE: ________________________  
 
STRÅLING:  
FELT: ____________________    DAGS DOSE: _____________   TOTAL DOSE: _________    
BEHANDLINGS START: __________________     BEHANDLINGS SLUTT: ________________ 
 
 
 
 
 
 
                                                                                                        DATO: _________ 
                                                                                                        DOSE: _________ 
 
AKUTTE BIVIRKNINGER 
 
Skjema for akutte bivirkninger etter RTOG-gradering og Koper et. al.,  skal nyttast  ved kontroll under pågående strålebehandling. 
 
TARM: 
 
0   ingen symptomer 
 
1   øket tarm tømming eller forandringer i avførings mønster, trenger ikke medikamenter 
 
2   diare, trenger medikamenter, ikke inkontinens, abdominal smerter trenger smertestillende. 
 
3   diare, trenger parenteral ernæring, slim/blod i avføring, trenger pads, utblåst abdomen ( røntgen abdomen viser oppblåste                
tarmslynger ) 
 
4   akutt eller subakutt obstruksjon/perforasjon, gastrointestinal blødning trenger blodtransfusion, abdominal smerter/tenesmus 
trenger tube decompression or bowel diversion 
 
 
ANAL: 
 
0   ingen symptomer 
 
1   ubehag/smerter, trenger ikke smertestillende 
 
2   ubehag/smerter, trenger smertestillende 
 
3   ubehag/ smerter, trenger opioider 
 
4   avlastande colostomi  
 
 
URINVEIER:  
 
0   ingen symptomer 
 
1   vannlatning/nocturi > 2x utgangspunkt, dysuri og urgency, trenger ikke medikamenter 
 
2   vannlatning/nocturi mindre en hver time, dysuri, urgency og blære spasmer trenger medikamenter 
 
3   vannlatning/nocturi > hver time, dysuri, smerter i bekkenregionen og blære spasmer, trenger opioider                               
regelmessig, hematuri 
 
4   hematuri trenger blodtransfusjon, akutt blære tamponade ( ikke sekundært til "clot" ), ulcerasjon eller necrose 
 
 
HUD: 
 
0   ingen forandringer 
 
1   rubor, tørr epitelitt 
 
2   mindre epitelitt ( til dels våt ), moderat ødem 
 
3   uttalt epitelitt ( våt ), pitting ødem 
 
4 sår, nekrose, hemorrhage 
 
 
 
BEHANDLING AV BIVIRKNINGER: 
REGISTRERINGSSKJEMA FOR SEIN-EFFEKTAR ETTER STRÅLEBEHANDLING AV 
PROSTATAKREFT. 
 
Pasientnamn: _________________________  Fødselsnummer: ____________ 
 
Kontroll(mnd): _________     Dato for konsultasjon: _________ Utført av: ________________ 
 
Generell status: 
 
Karnofsky-status: _____________   Vekt(kg):________                 PSA:________ 
 
Skjema for status for normalvev på dei påfølgjande sider har 4 klassifiseringar: RTOG-gradering samt S, O og M-kategorisering i frå 
LENT/SOMA. Skjemaet skal nyttast ved kontrollar   etter 6, 12, 24 og 60 mnd, etter utført strålebehandling. 
  
 
Blære og urethra : 
 
 0  Grad 1  Grad 2 Grad 3 Grad 4 5 
RTOG ingen Slight epithelial atrophy; 
minor telangiectasia 
(microscopic hematuria) 
Moderate frequency; 
generalized telangiectasia; 
intermittent macroscopic 
hematuria  
Severe frequency & 
dysuria; severe generalized 
telangiectasia (often with 
petechiae); frequent 
hematuria; reduction in 
bladder capacity (< 150cc) 
 
Necrosis/Contracted 
bladder (capacity < 100 cc) 
Severe hemorrhagic cystitis 
Mors 
Subjektiv 
    
   Dysuri 
 
   Miksjonsfrekvens 
 
   Hematuri 
 
   Inkontinens 
 
    
   Strålefylde  
 
 
ingen 
 
 
 
Sjelden 
 
3-4 timer 
 
Sjelden 
 
< 1 / uke 
 
 
Av og til nedsatt 
 
 
 
Vekslende 
 
2-3 timer 
 
Vekslende 
 
< 1 / dag 
 
 
Nedsatt 
 
 
Vedvarende 
 
1-2 timer 
 
Vedvarende 
 
< 2 truser / dag 
 
 
Delvis stopp 
 
 
Betydelig 
 
Hver time 
 
Betydelig 
 
Betydelig 
 
 
Total stopp 
Mors 
Objektiv  
    
   Hematuri 
 
       
   Endoscopi 
 
    
    
   Maksimalt volum 
 
   Residualvolum 
 
ingen  
 
Mikroskopisk 
 
 
Flekket atrofi / 
teleangiektasier uten 
blødning 
 
 >300-400 cm3 
 
<25 cm3 
 
 
Sjelden makroskopisk 
 
 
Stor atrofi / teleangiektasier 
med blødning 
 
 
 >200-300 cm3 
 
> 25-100 cm3 
 
 
Makroskopisk 
 
 
Ulcerasjon i muskulatur  
 
 
 
 >100-200 cm3 
 
> 100 cm3 
 
 
Makroskopisk med koagler 
 
 
Perforasjon eller fistel  
 
 
 
< 100 cm3 
 
Urinretensjon 
Mors 
Tiltak  
 
  Dysuri 
 
   Miksjonsfrekvens 
 
 
   Hematuri 
 
 
   Inkontinens 
 
 
    
   Urinstråle  
 
ingen  
 
Sjelden perifert virkende 
analgetika 
 
Alkalisering av urinen 
 
 
Jernmedikasjon 
 
 
Sjelden bleier 
 
 
 
Redusert kraft på 
urinstrålen 
 
 
 
Jevnlig perifert virkende 
analgetika 
 
Sjelden spasmolytika 
 
 
En transfusjon eller 
kauteriser 
 
Hyppig bleier 
 
 
 
Ren intermitterende 
kateterisering < 1/dag 
 
 
Jevnlig sentralt virkende 
analgetika 
 
Jevnlig sentralt virkende 
analgetika 
 
Jevnlig transfusjon eller 
koaguler 
 
Alltid bleier eller ren 
intermitterende 
kateterisering 
 
Dilatasjon eller ren 
intermitterende 
katetrisering > 1/dag 
 
 
Kirurgisk behandling 
 
 
Cystektomi 
 
 
Kirurgisk intervensjon 
 
 
Permanent kateter 
 
 
 
Foleykateter eller kirurgi 
Mors 
 
Side 1 av 6 
 
Rektum-status: 
 
 0  Grad 1  Grad 2 Grad 3 Grad 4 5 
RTOG None Mild diarrhea; mild 
cramping; bowel movement 
5 times daily; slight rectal 
discharge or bleeding 
Moderate diarrhea and 
colic; bowel movement > 5 
times daily; excessive rectal 
mucus or intermittent 
bleeding  
 
Obstruction or bleeding, 
requiring surgery 
Necrosis/perforation fistula Death 
Subjektiv 
    
   Tenesmer 
 
   Slim i avføring 
 
   Sphincter kontroll 
 
   Avføringsfrekvens 
 
   Smerter  
 
ingen 
 
 
 
Sjelden 
 
Sjelden  
 
Sjelden 
 
2-4 / døgn 
 
Sjelden 
 
 
Vekslende 
 
Vekslende  
 
Vekslende 
 
4-8 / døgn 
 
Vekslende 
 
 
Vedvarende 
 
Vedvarende  
 
Vedvarende  
 
> 8 / døgn  
 
Vedvarende 
 
 
Uttalt 
 
Uttalt 
 
Uttalt 
 
Ukontrollert diare 
 
Uttalt 
Mors 
Objektiv  
    
   Blødning 
      
   Ulcerasjon 
      
   Striktur   
ingen  
 
Kjemisk påvist 
 
Overflatisk < 1 cm2 
 
> 2/3 av normal diameter 
med dilatasjon 
 
 
 > 2 / uke  
 
Overflatisk > 1 cm2 
 
1/3 - 2/3 av normal 
diameter med dilatasjon 
 
 
 
Vedvarende eller daglig 
 
Dyp ulcerasjon 
 
< 1/3 av normal diameter 
 
 
Større blødning  
 
Perforasjon eller fistle 
 
Total obstruksjon 
Mors 
Tiltak  
 
  Tenesmer og 
tømmefrekvens   
 
   Smerter 
 
 
   Blødning 
 
    
   Ulcerasjon 
 
    
   Striktur 
 
 
   Sphincter kontroll 
 
ingen  
 
 ≤ 2 / uke med 
antidiaremiddel 
 
Sjelden perifert virkende 
analgetika 
 
Stool softener, iron therapy 
 
 
Diett eller laksantia 
 
 
Diett 
 
 
Sjelden bleier 
 
 
> 2 / uke med 
antidiaremiddel 
 
Regelmessig perifert 
virkende analgetika 
 
Sjelden transfusjon 
 
 
Periodevis steroider 
 
 
Sjelden dilatasjon 
 
 
Hyppig bleier 
 
 
¾ 2 / dag med 
antidiaremiddel 
 
Jevnlig sentralt virkende 
analgetika 
 
Jevnlig transfusjon 
 
 
Steroidklyster, Hyperbar O2
 
 
Regelmessig dilatasjon 
 
 
Alltid bleier  
 
  
 
 
 
Kirurgisk terapi, eventuell 
kolostomi 
 
Kirurgisk terapi, eventuell 
kolostomi 
 
Kirurgisk terapi, eventuell 
kolostomi 
 
Kirurgisk terapi, eventuell 
kolostomi 
 
Kirurgisk terapi, eventuell 
kolostomoi 
 
Kirurgisk terapi, eventuell 
kolostomi 
Mors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Side 2 av 6 
 
 
 
 
Tarmstatus: 
 
 0  Grad 1  Grad 2 Grad 3 Grad 4 5 
RTOG None Mild diarrhea; mild 
cramping; bowel movement 
5 times daily; slight rectal 
discharge or bleeding 
Moderate diarrhea and 
colic; bowel movement > 5 
times daily; excessive rectal 
mucus or intermittent 
bleeding  
 
Obstruction or bleeding, 
requiring surgery 
Necrosis/perforation fistula Death 
Subjektive 
    
   Avføringsfrekvens 
 
   Avføringskonsistent 
 
   Smerter 
 
   Obstipation 
 
ingen 
 
 
 
2-4 / døgn 
 
Bulky  
 
Sjelden 
 
3-4 / uke 
 
 
5-8 / døgn 
 
Løs  
 
Vekslende 
 
2 / uke 
 
 
> 8 / døgn 
 
Slim, mørk, vann  
 
Vedvarende 
 
1 / uke 
 
 
Ukontrollert diare 
 
 
 
Uttalt 
 
> 10 døgn 
Mors 
Objektive  
    
   Melena 
      
 
   Vekttap fra 
oppstart av 
behandling 
      
   Striktur   
 
    
   Ulcerasjon 
 
ingen  
 
Sjelden 
 
 
≥ 5-10% 
 
 
 
> 2/3 av normal diameter 
med dilatasjon 
 
Overflatisk ≤ 1 cm2 
 
 
Vekslende, normal 
hemoglobin  
 
¾ 10-20% 
 
 
 
1/3 - 2/3 av normal 
diameter med dilatasjon 
 
Overflatisk > 1 cm2 
 
 
Vedvarende, 10-20% ned i  
hemoglobin 
 
> 20-30% 
 
 
 
< 1/3 av normal diameter 
 
 
Dyp ulcerasjon 
 
 
Uttalt, > 20% ned i 
hemoglobin 
  
> 20-30% 
 
 
 
Total obstruksjon 
 
 
Perforasjon eller fistle 
Mors 
Tiltak  
 
  Smerter 
 
 
   Tømmefrekvens / 
konsistent 
 
 
   Blødning 
 
   Striktur  
 
    
   Ulcerasjon 
 
ingen  
 
Sjelden perifert virkende 
analgetika 
 
Diet modifikasjon 
 
 
 
Jern behandling 
 
Sjelden diet modifikasjon 
 
 
Regelmessig perifert 
virkende analgetika 
 
Regelmessig perifert 
virkende analgetika, 
antidiaremiddel 
 
Periodevis transfusion 
 
Diet modifikasjon 
nødvendig 
 
 
 
Jevnlig sentralt virkende 
analgetika 
 
Jevnlig sentral virkende 
analgetika, antidiaremiddel 
 
 
Jevnlig transfusion  
 
Medical intervention, NG 
suction 
 
Medical intervention 
 
 
Kirurgisk terapi, eventuell 
kolostomi 
 
 
 
 
 
Kirurgisk terapi 
 
Kirurgisk terapi 
 
Kirurgisk terapi 
Mors 
 
 
 
 
 
 
 
 
 
 
 
 
 
Side 3 av 6 
 
Hoftebein-status: 
 
  0  Grad 1  Grad 2 Grad 3 Grad 4 5 
RTOG  Asymptomatic; no growth 
retardation; reduced bone 
density 
Moderate pain or 
tenderness; growth 
retardation; irregular bone 
sclerosis 
 
Sever pain or tenderness; 
complete arrest of bone 
growth; dense bone 
sclerosis 
Necrosis/Spontaneous 
fracture 
Death 
Subjektiv 
 
Smerter 
 
Funksjon 
 
 
Ledd bevegelse 
Ingen 
 
 
 
Sjelden 
 
Interferes with athletic 
recreation  
 
Stiffness interfering with 
athletic recreation 
 
 
Vekslende 
 
Interferes with work 
 
 
Stiffness interfering with 
work 
 
 
Vedvarende 
 
Interferes with daily activity 
 
 
Stiffness interfering with 
daily activity 
 
 
Betydelig 
 
Complete lack of function 
 
 
Complete fixation, necrosis 
Mors 
Objektiv 
 
Brudd 
 
Mucosa soft tissue 
 
Hud over bone 
 
Ledd bevegelse 
 
Ingen 
 
 
 
 
 
 
 
Erythema 
 
< 10% mindre 
 
 
 
 
 
 
Sår 
 
< 10 - 30% mindre 
 
 
Partial thickness 
 
Sequestration 
 
Sinus 
 
< 30 - 80% mindre 
 
 
Full thickness 
 
 
 
Fistula 
 
> 80% mindre 
Mors 
Tiltak 
 
Smerter 
 
 
Funksjon 
 
 
Ledd bevegelse 
Ingen  
 
Sjelden perifert virkende 
analgetika 
 
Sjelden fysioterapi 
 
 
Sjelden fysioterapi 
 
 
Regelmessig perifert 
virkende analgetika 
 
Periodevis fysioterapi 
 
 
Intensive fysioterapi 
 
 
Jevnlig sentralt virkende 
analgetika 
 
Regelmessig fysioterapi 
eller medisinsk terapi 
 
Kirurgisk terapi 
 
 
Kirurgisk terapi 
 
 
Kirurgisk terapi 
 
 
 
 
Mors 
 
 
 
 
 
SEKSUELL DYSFUNKSJON: 
 
 0        Grad 1         Grad 2         Grad 3         Grad 4 
Subjektive 
 
Erectile function for 
vaginal penetration 
 
Dryness 
 
Desire 
 
Satisfaction 
 
Ingen  
 
 
Occasionally insufficient 
 
 
Occcasional 
 
Occasional 
 
Occasional 
 
 
Intermittently insufficient 
 
 
Intermittent 
 
Intermittent 
 
Intermittent 
 
 
 
Not sufficient 
 
 
Persistent 
 
Seldom 
 
Seldom 
 
 
Impotent 
 
 
Refractory 
 
Never 
 
Never 
Objektive 
 
Frequency 
 
Orgasm 
 
Ingen  
 
 
 
Occasional 
 
 
 
Decreased form normal 
 
Intermittent 
 
 
 
Rare 
 
Seldom 
 
 
 
Never 
 
Never 
Tiltak 
 
Impotence 
 
Ingen 
 
  
 
Medikal terapi 
 
 
Kirurgisk terapi 
 
 
 
 
Side 4 av 6 
 
 
BEHANDLING PGA. SEIN-EFFEKTAR ( JA / NEI ): 
 
HVIS JA; HVILKEN BEHANDLING: 
 
 
RESIDIV ( JA / NEI / USIKKER):                       hvis ja, dato: 
 
 
STIGENDE PSA (3 siste PSA med dato):  
 
LOKALT: 
 
DISTALT ( bein, visceral, lymph node,annet ): 
 
 
STARTET BEHANDLING PGA. RESIDIV ( JA / NEI ): 
 
DATO: 
 
HVILKEN BEHANDLING: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Side 5 av 6 
 STATUS (%)                KARNOFSKY PERFORMANCE STATUS SCORE
 
100%                      Normal; no complain 
 
 
 
 
 
 
 
 
 
 
90%                       Able to carry on normal activities; minor signs or symptom of disease 
80%                       Normal activity with effort 
70%                       Cares for selv; unable to carry on normal activity or to do active work 
60%                       Requires occasional assistance but able to care for most of his needs 
50%                       Requires considerable assistance and frequent medical care 
40%                       Disabled; requires special care and assistance 
30%                       Severely disabled; hospitalization indicated though death is not imminent 
20%                       Very sick; hospitalization necessary; active supportive treatment necessary 
10%                       Moribund 
0%                        Dead 
Side 6 av 6 
